Immunogenic CD19 peptides

Details Immunogenic CD19 peptides Immunogenic CD19 peptides

2011-04-05

2011-04-05

Yu, Misook (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C424S184100, C514S002600

Reexamination Certificate

active

07919576

ABSTRACT:
The invention provides relatively short immunogenic peptides derived from CD19 antigens, and biologically active variants thereof, which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provided. The immunogenic peptides can be included in pharmaceutical compositions, such as cancer vaccines, and used for the treatment of cancer.

REFERENCES:
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4777127 (1988-10-01), Suni et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5939526 (1999-08-01), Gaugler et al.
patent: 6271019 (2001-08-01), Van Baren et al.
patent: 6291430 (2001-09-01), Chaux et al.
patent: 6306640 (2001-10-01), Nicolette
patent: 6344203 (2002-02-01), Sandrin et al.
patent: 6440386 (2002-08-01), Leung et al.
patent: 2003/0206916 (2003-11-01), Bae et al.
patent: 0345242 (1989-12-01), None
patent: 2200651 (1988-08-01), None
patent: WO 89/01973 (1989-03-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 91/02805 (1991-03-01), None
Harig et al, Blood, vol. 98, p. 2999-3005, 2001.
Tedder et al , J Immunol vol. 143, p. 712-717, 1989.
Algino et al., “CD20 (pan-B cell antigen) expression on bone marrow-derived cells”Am J Clin Pathol106(1):78-81, Jul. 1996 (abstract).
Altman JD et al, “Phenotypic analysis of antigen-specific T lymphocytes”Science274:94-96, 1996 (abstract).
Bakker et al, “Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro”Cancer Res55: 5330-5334, 1995 (abstract).
Baur MP et al., “Genetic analysis of IDDM: the GAW5 multiplex family dataset”Genet Epidemiol6: 15-20, 1989 (abstract).
Beatty GL et al., “Regulation of tumor growth by IFN-gamma in cancer immunotherapy” Immunol Res 24: 201-210, 2001 (abstract).
Bejcek et al., “Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against ehe CD19 antigen”Cancer Res55 (11): 2346-2351, 1995 (abstract).
Berkner, “Development of adenovirus vectors for the expression of heterologous genes”Biotechniques6: 616-627, 1988.
Bordignon, “Retroviral vector-mediated high-efficiency expression of adenosine deminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells”Proc Natl Acad Sci USA86: 6748-52, 1989.
Brossart P et al., “Selective activation of Fas/Fas ligand-mediated bytotoxicity by a self peptide”J Exp Med183: 2449-2458, 1996 (abstract).
Chen et al.,“ Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen”Proc Natl Acad Sci USA88: 110-114, 1991 (abstract).
Correll et al., “Production of human glucocerebrosidase in mice after retrovira gene transfer into multipotential hematopoietic progenitor cells”Proc Natl Aced Sci USA86, p. 8912, 1989 (abstract).
Coulie et al., “Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination?”Stem Cells13: 393-403, 1995 (abstract).
Culver K, “Lymphocytes as cellular vehicles for gene therapy in mouse and man” Proc Natl Acad Sci USA 88, p. 3155, 1991.
Dörken et al., “Leucocyte Typing IV: White Cell Differentiation Antigens,” In: Knapp W., Dörken B, Gilks WR et al., eds. Leucocyte Typing IV:White Cell Differentiation Antigens. Oxford: Oxford University Press: 46-48, 1989.
Einfeld et al.,“ Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains”EMBO J7 (3): 711-717, 1988 (abstract).
Fisher-Hoch et al, “Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene”Proc Natl Acad Sci86: 317-321, 1989 (abstract).
Flexner et al., “Vaccinia virus expression vectors”Ann NY Acad Sci569: 86-103, 1989.
Flexner et al., “Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2”Vaccine8: 17-21, 1990 (abstract).
Freeman et al, Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferationScience262: 909-991, 1993 (abstract).
Gajewski et al., “Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous PlMC plus rhIL-12”Clin Cancer Res7, p. 895, 2001.
Gene Expression Technology, Goeddel ed., Academic Press, Inc., 1991.
Gomez-Nunez et al., “Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A *0201 molecules,”Leukemia Research30 (2006), 1293-1298.
Greenberg J, “Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia”Immunol136 (5), p. 1917, 1986 (abstract).
Grube, M et al., “Are Normally Expressed B-Cell Differentiation Antigens Possible Target Antigens for Cellular Immunotherapy in B-Cell Malignancies?” Abstracts of the 44thAnnual Meeting of the Amer Soc of Hematology, Philadelphia, Dec. 2002.
Grube, M et al., “Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies,”Clin Cancer Res10 (3): 1047-1056, 2004.
Guzman et al., “Efficient and selective adenovirus-mediated gene transfer into vascular neointima”Circulation88: 2838-2848, 1993 (abstract).
Guzman et al., “Efficient gene transfer into myocardium by direct injection of adenovirus vectors”Cir Res73: 1202-1207, 1993 (abstract).
H.G. Rammensee et al., MHC Ligands and Peptide Motifs, LandesBioscience, 1997.
Hall, “IL-12 at the crossroads” Science 268: 1432-1434, 1995.
Harper et al.,J of Immunology147:1037-1044 and NCBI accession No. 2134978, 1991.
Hassainya, Y. et al “Identification of Naturally Processed HLA-A2—Restricted Proinsulin Epitopes by Reverse Immunology,”Diabetes, vol. 54, Jul. 2005; published by American Diabetes Association.
Herlyn et al., “Anti-idiotypic antibodies bear the internal image of a human tumor antigen”Science232, p. 100, 1986 (abstract).
Hoojberg et al.,J Immunother Emphais Tumor ImmunolSuppl 2:43-45, 1996.
Hopp et al., “A short polypeptide marker sequence useful for recombinant protein and purification”BioTechnology6, p. 1204, 1988.
Houbiers JG et al, “In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53”Eur J Immunol23: 2072-2077, 1993 (abstract).
Hultin et al., “CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes”Cytometry14: 196-204, 1993 (abstract).
Ikeda H et al., “The roles of IFN gamma in protection against tumor development and cancer immunoediting”Cytokine Growth Factor Rev13: 95-109, 2002 (abstract).
Kass-Eisler et al., “Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo”Proc Natl Acad Sci90: 11498-11502, 1993 (abstract).
Kast et al., “Eradicaton of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes”Cell59: 603-614, 1989.
Kolls et al., “Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer”Proc Natl Acad Sci91: 215-219, 1994 (abstract).
Lau et al., “Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma”J Immun24 (1), p. 66, 2001 (abstract).
Liu et al, “A BsmFI PCR/RFLP in the canine CD19 gene”Anim Genet29(1): 64-65, 1998.
Lodge et al., “Dendritic cell-based immunotherapy of prostate cancer: immune mon

Affiliated with

Also associated with

Rating

Immunogenic CD19 peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic CD19 peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic CD19 peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2658819